Osmol Therapeutics, Inc. — Form D
Osmol Therapeutics, Inc. of NEW HAVEN, CT, a company, filed a Form D exempt-offering notice with the SEC on 2022-02-28. The offering totals $7.5M, of which $2.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-02-28
- Form: D
- Accession: 0001694244-22-000001
- Industry: Biotechnology
- Exemptions: 06c
- Total offering: $7.5M
- Amount sold: $2.3M
- Remaining: $5.2M
- Investors: 4
- Date of first sale: 2022-02-14
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-435142
Issuer
- Name: Osmol Therapeutics, Inc.
- CIK: 0001694244
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 33 WHITNEY AVENUE, NEW HAVEN, CT, 06510
- Phone: 617-719-9406
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Robert Berman | Director | New York, NY |
| Vlad Coric | Director | Baltimore, MD |
| Michael Ehrlich | Director | New Haven, CT |
| Robert Linke | Director | New Haven, CT |
| Robert Linke | Executive Officer | New Haven, CT |
| Brian Dixon | Director | Orlando, FL |
| Brian Dixon | Executive Officer | Orlando, FL |
Other filings by this issuer (1)
More